AbbVie is successfully replacing Humira with fast-growing immunology and neuroscience assets, supporting a Buy view despite heavy debt and a rich valuation. Skyrizi, Rinvoq, and neuroscience growth are offsetting legacy erosion and keeping earnings momentum intact.
Investment thesis: AbbVie (ABBV) has successfully replaced much of its Humira revenue with fast-growing immunology products, while neuroscience provides a second growth engine. Skyrizi generated $5.5 billion in second-quarter 2026 sales, up 24% operationally, and Rinvoq produced more than $2.5 billion, up 23.7%. Neuroscience revenue exceeded $3.2 billion and grew about 20% operationally. This portfolio momentum supports a Buy view for a moderate-risk investor, although $69.1 billion of debt, negative book value per share of $3.36, product concentration, and a trailing P/E of 69.5x limit the margin of safety.
The operating evidence is strong. Second-quarter revenue reached $17.0 billion, up 10.2%, while adjusted EPS came in at $3.65, $0.06 above management's guidance midpoint. AbbVie raised full-year 2026 revenue guidance to approximately $67.6 billion and projected adjusted EPS of $13.87 to $14.07. The company has also beaten EPS estimates in seven of the past eight reported quarters.
The investment case is therefore a transition story with cash-flow support, not a bargain-bin recovery. The quoted share price is $259.10, compared with an analyst consensus target of $274.36. That modest gap favors disciplined accumulation rather than aggressive chasing, especially because the planned $10.9 billion Apogee Therapeutics acquisition adds pipeline depth but also brings $0.14 of anticipated 2026 adjusted EPS dilution.
AbbVie is a research-based biopharmaceutical company headquartered in North Chicago, Illinois. Incorporated in 2012, the company employs approximately 57,000 people and researches, manufactures, commercializes, and sells medicines and therapies worldwide.
The portfolio spans immunology, neuroscience, oncology, aesthetics, eye care, gastroenterology, and specialty medicines. Core products include Skyrizi and Rinvoq in inflammatory disease; Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, and Vyalev in neuroscience; Venclexta, Imbruvica, Elahere, Epkinly, and Emrelis in oncology; and Botox Cosmetic and Juvederm in aesthetics.
AbbVie's business model combines high-value specialty medicines with established commercial infrastructure. Full-year 2025 segment revenue was $30.4 billion in immunology, $10.8 billion in neuroscience, $6.7 billion in oncology, and $4.9 billion in aesthetics. That mix gives ABBV multiple revenue streams, but Skyrizi and Rinvoq have become essential to the company's growth profile as Humira faces biosimilar erosion.
Immunology is the central growth engine. Second-quarter immunology revenue was nearly $8.8 billion, with operational growth of 14.6%. Skyrizi and Rinvoq supplied the momentum, while Humira revenue fell to $706 million, down 36.1% operationally because of biosimilar competition.
Neuroscience is the strongest secondary engine. Revenue exceeded $3.2 billion in the second quarter, with Vraylar sales near $1.1 billion and growth of approximately 19%. Botox Therapeutic, Ubrelvy, and Qulipta each posted double-digit sales growth, while Vyalev sales reached $256 million, up more than 27% sequentially.
Oncology remains a mixed portfolio. Second-quarter revenue exceeded $1.6 billion but declined 2.4% operationally. Venclexta sales rose 9.6% to $771 million, and Elahere, Epkinly, and Emrelis posted double-digit growth. Imbruvica declined 29.4% because of IRA pricing and competitive share pressure.
Aesthetics is smaller and more cyclical. Second-quarter sales were nearly $1.3 billion, down 0.9% operationally. Botox Cosmetic revenue rose 3.4% to $728 million, while Juvederm revenue fell 6.6% to $245 million. The contrast shows why aesthetics adds diversification but does not carry the same earnings durability as prescription immunology.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Skyrizi is AbbVie's flagship asset and the clearest proof that the Humira transition is working. Full-year 2025 Skyrizi revenue was $17.6 billion. Second-quarter 2026 sales reached $5.5 billion, up 24% operationally, and management raised the full-year revenue outlook to $21.7 billion.
Skyrizi's commercial advantage rests on efficacy, durability, and convenience. AbbVie reported market-share leadership in more than 30 countries and said Skyrizi captures new and switching psoriasis patients at a rate four times higher than any other biologic or oral treatment in the U.S. Quarterly dosing, durable skin clearance, five years of psoriatic arthritis data, and a pediatric weight-based dosing option strengthen physician familiarity.
Inflammatory bowel disease broadens the product's runway. Skyrizi is capturing a leading share of new U.S. patient starts in Crohn's disease and ulcerative colitis. The subcutaneous Crohn's induction regimen produced endoscopic response and clinical remission rates 25 percentage points above placebo in the overall population and 45 points above placebo among patients without prior advanced therapy.
AbbVie's moat combines established brands, specialty-care expertise, regulatory experience, and a large commercial organization. Skyrizi's performance in more than 30 countries and Rinvoq's 23.7% operational sales growth demonstrate that the company can scale new indications after launch, rather than relying only on legacy products.
Rinvoq's innovation case extends across gastroenterology and dermatology. European approvals cover severe alopecia and non-segmental vitiligo, while U.S. applications are under review. AbbVie estimates combined peak sales for those two indications near $2 billion. The company also has Phase 3 programs in hidradenitis suppurativa and a planned combination strategy pairing Skyrizi with an alpha-4 beta-7 antibody and a TL1A antibody.
External business development adds another layer. AbbVie announced a $10.9 billion all-cash acquisition of Apogee Therapeutics to add late-stage assets in atopic dermatitis, asthma, and related inflammatory diseases. Management described the deal as dilutive to adjusted EPS in 2026 and 2027 and accretive beginning in 2032. That timeline makes the transaction a long-term pipeline investment rather than an immediate earnings catalyst.
AbbVie operates an integrated research, manufacturing, and commercialization model across worldwide markets. The company employs about 57,000 people, giving it scale across clinical development, regulatory affairs, production, and specialty sales. Its established infrastructure supports products ranging from biologics such as Skyrizi to injectables, oral medicines, and oncology therapies.
The second-quarter call provided a specific manufacturing read-through for Skyrizi's proposed subcutaneous Crohn's induction option. AbbVie said the product is well known to health authorities, manufacturing is well known internally, and the submission is proceeding according to plan. That combination reduces execution friction for a key lifecycle expansion.
Capital allocation also affects operating flexibility. Second-quarter operating cash flow was $3.4 billion and free cash flow was $3.2 billion. Management secured interim financing for Apogee and expects to issue long-term debt, while targeting a net leverage ratio of 2.0x within two to three years after closing.
AbbVie participates in large chronic-disease markets where recurring treatment and specialty-care adoption support durable demand. The strongest evidence is internal: immunology revenue grew 14.6% operationally in the second quarter, neuroscience grew approximately 20%, and full-year 2025 revenue rose 8.6% to $61.2 billion.
The market opportunity is expanding through new indications rather than one product alone. Skyrizi is moving deeper into Crohn's disease and ulcerative colitis. Rinvoq is extending into vitiligo, alopecia areata, and other inflammatory diseases. In neuroscience, Qulipta received European approval for acute migraine, and the oral CGRP portfolio has a stated peak-sales objective above $5 billion.
Aesthetics adds exposure to an underpenetrated but more discretionary market. AbbVie describes Botox Cosmetic as an industry-leading franchise and expects the short-acting toxin BoE to expand the toxin category after European and Canadian approvals. The 2025 decline in aesthetics revenue and the second-quarter Juvederm decline show that category growth can vary materially by product and geography.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
AbbVie's primary healthcare customers include patients with chronic inflammatory disease, migraine, psychiatric disorders, Parkinson's disease, blood cancers, and other specialty conditions. Skyrizi and Rinvoq serve psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and other immune-mediated illnesses. These indications create recurring treatment demand and make physician experience a central commercial asset.
Prescribers are a critical decision group. AbbVie reported that Skyrizi captured a leading share of new patient starts in inflammatory bowel disease and maintained strong new and switching patient share in psoriasis. Management called frontline IBD adoption the clearest signal of physician preference.
Aesthetics serves a different customer profile. Botox Cosmetic and Juvederm depend on elective procedures and clinician adoption, while BoE is designed to let patients preview the effect of a short-duration toxin. This creates a potential entry point for new users, but the 2025 Juvederm decline illustrates the greater sensitivity of aesthetic demand to market conditions.
AbbVie faces major research-based competitors across each franchise. Johnson & Johnson (JNJ), Eli Lilly (LLY), Novartis (NVS), Amgen (AMGN), and Bristol Myers Squibb (BMY) compete in immunology. Oncology competition includes BMY, Amgen, Gilead Sciences (GILD), JNJ, and Roche. Neuroscience competitors include LLY, Biogen (BIIB), UCB, and Jazz Pharmaceuticals (JAZZ).
In aesthetics, Galderma, Revance, Merz, and Evolus compete with Botox Cosmetic and Juvederm. AbbVie's advantage is the breadth of its commercial platform and the strength of Botox as both a cosmetic and therapeutic franchise. Its disadvantage is that crowded categories force continuous investment in efficacy, indications, convenience, and physician education.
The competitive record is uneven by product. Skyrizi and Rinvoq are expanding rapidly, Venclexta grew 9.6% operationally in the second quarter, and Elahere, Epkinly, and Emrelis posted double-digit growth. Humira declined 36.1% and Imbruvica declined 29.4%. The portfolio is winning where innovation is current and losing where exclusivity and pricing pressure are more advanced.
Government pricing policy is already affecting ABBV. Management attributed Imbruvica's 29.4% operational decline in the second quarter partly to IRA pricing. That result demonstrates how policy can create a direct earnings headwind even when a product remains commercially established.
Foreign exchange also affects reported growth. Currency provided a 0.7% favorable impact to second-quarter sales, while AbbVie assumes approximately a 0.5% favorable effect on full-year 2026 revenue growth. The small contribution means the current growth case rests mainly on product demand rather than currency.
Interest rates and financing conditions matter because AbbVie is funding the Apogee acquisition with debt. Management projected 2026 net interest expense of approximately $2.9 billion, up $200 million, and committed to reducing net leverage to 2.0x within two to three years after the transaction closes. Strong operating cash flow supports that plan, but the balance sheet leaves less room for execution errors than a debt-light pharmaceutical model.
AbbVie carries $69.1 billion of debt and negative book value per share of $3.36, leaving the balance sheet less flexible than the company’s operating momentum.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Second-quarter revenue rose 10.2% to $17.0 billion and adjusted EPS of $3.65 beat guidance by $0.06, extending a run of seven EPS beats in the last eight quarters.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 revenue guidance to about $67.6 billion and EPS guidance to $13.87-$14.07 after Skyrizi delivered $5.5 billion in quarterly sales.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →AbbVie trades at a trailing P/E of 69.5x, so the case hinges on whether fast-growing immunology and neuroscience can justify the premium.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The shares at $259.10 sit below the $274.36 analyst consensus target, suggesting disciplined accumulation rather than aggressive chasing.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →AbbVie has turned a major patent-loss challenge into a credible growth platform. Skyrizi and Rinvoq now lead the transition, neuroscience is expanding at approximately 20%, and management has raised 2026 revenue guidance to $67.6 billion after a second-quarter revenue beat.
The counterweight is financial structure. Debt of $69.1 billion, cash of $5.3 billion, a 0.67 current ratio, negative equity, Humira's 36.1% operational decline, and Imbruvica's 29.4% decline all require disciplined valuation. Strong operating cash flow of $19.0 billion and free cash flow of $17.8 billion keep the risk manageable, but they do not erase it.
At $259.10, ABBV merits a Buy rating for a medium-term investor because forward earnings growth and pipeline depth outweigh the balance-sheet concerns by a modest margin. The $275.00 central target leaves room for upside without pretending that a mature, heavily indebted pharmaceutical company deserves an unlimited growth multiple.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Marc Lichtenfeld and The Oxford Club are promoting the Ultimate Dividend Package, a free bundle of five dividend-stock reports. We identify the best matches and test the income claims against filings.
AbbVie is showing that its post-Humira rebuild is real, with Skyrizi and Rinvoq driving strong growth and full-year guidance moving higher. Heavy debt and a negative equity position remain the main risks, but cash flow and earnings power still look compelling.
AbbVie Inc. (ABBV) rises after announcing a $10.9 billion all-cash acquisition of Apogee Therapeutics. The deal expands AbbVie’s immunology pipeline and reinforces its post-Humira growth strategy, while strong recent earnings and raised guidance add support to the rally.